OCT-1 as a determinant of response to antileukemic treatment

Clin Pharmacol Ther. 2011 Apr;89(4):608-11. doi: 10.1038/clpt.2011.12. Epub 2011 Feb 23.

Authors

J R Engler¹, T P Hughes, D L White

Affiliation

¹ Department of Haematology, SA Pathology (RAH Campus), Adelaide, Australia.

PMID: 21346750
DOI: 10.1038/clpt.2011.12

No abstract available

MeSH terms

Antineoplastic Agents / pharmacology*
Benzamides
Drug Resistance, Neoplasm
Humans
Imatinib Mesylate
Leukemia, Myeloid, Chronic-Phase / drug therapy*
Leukemia, Myeloid, Chronic-Phase / pathology
Organic Cation Transporter 1 / metabolism*
Piperazines / pharmacology*
Protein Kinase Inhibitors / pharmacology*
Pyrimidines / pharmacology*

Substances

Antineoplastic Agents
Benzamides
Organic Cation Transporter 1
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate